January 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for ...

The drug was first approved in the 1990s and is currently marketed by Eli Lilly under the brand name Zyprexa. Teva, which launched a Dr. Reddy’s-partnered generic to Zyprexa in 2011, spotted a ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in the United ...

Teva Pharmaceuticals’ TEV-479 (olanzapine ... in 2009. It is marketed by Eli Lilly as Zyprexa and a longer-acting version ...

On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available ... That puts Emgality ahead of Teva’s Ajovy (fremanezumab), which picked up a positive opinion ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA.

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available ... That puts Emgality ahead of Teva’s Ajovy (fremanezumab), which picked up a positive opinion ...